

STATEMENT BY APPLICANT

(use ⁴¹ as many sheets as necessary)

Sheet

1

of

2

Application Number

10/550,532

Filing Date

September 22, 2005

First Named Inventor

Le T. Duong

Group Art Unit

To be assigned

Examiner Name

To be assigned

Attorney Docket Number

21259YP

**Examine
Initials***

Cite
No.

U.S. Patent Document

Number

Kind
Code
(if known)Name of Patentee or Applicant
of Cited Document

**Date of Publication of
Cited Document
MM-DD-YYYY**

/G.H./

6,008,207

Brenner, GS et al.

12/28/1999

Examiner
Initials*Cite
No.

Foreign Patent Document

Office

Number

Kind
Code
(if known)Name of Patentee or Applicant
of Cited Document

**Date of Publication of
Cited Document
MM-DD-YYYY**

**Examiner
Signature**

/Gigi Huang/

Date Considered

11/12/2007

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P.O., Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Substitute for form 1449B/P.T.O.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/550,532
---------------------------	------------

Filing Date	September 22, 2005
--------------------	---------------------------

First Named Inventor	Le T. Duong
-----------------------------	--------------------

Group Art Unit	To be assigned
----------------	----------------

Examiner Name	To be assigned
---------------	----------------

Attorney Docket Number 21259YP

Sheet

2

of

2

NON PATENT LITERATURE DOCUMENTS

Examiner
Initials*Cite
No.

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

/G.H./

Lehmann, HJ et al., *Annals of the Rheumatic Diseases*, p 530-533 (2002), "Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products"

/G.H./

Garnero, P et al., Bone, p 461-464 (2001), "The bisphosphonate zoledronate decreases Type II collagen breakdown in patients with Paget's disease of bone"

/G.H./

Muehleman, C et al., Osteoarthritis and Cartilage, p 226-233 (2002), "The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage"

/G.H./

Podworny, NV et al., The Journal of Rheumatology, p 1972-1982 (1999), "Partial chondroprotective effect of zoledronate in a rabbit model of inflammatory arthritis"

/G.H./

Myers, SL et al., The Journal of Rheumatology, p 2645-2653 (1999), "Effects of a bisphosphonate on bone histomorphometry and dynamics in the canine cruciate deficiency model of osteoarthritis"

**Examiner
Signature**

/Gigi Huang/

Date Considered

11/12/2007

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005